Trial reportCannabis and cannabinoid research2022
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Open access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Cannabis and cannabinoid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2025Pooled it
- The impact of cannabis on immune checkpoint inhibitor therapy: a systematic review of immunomodulatory effects of cannabis in patients with and without cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review.Current neuropharmacology · 2023Pooled it
- Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review.Clinical drug investigation · 2022Pooled it
- An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis.Scientific reports · 2024Trial
- Exploring potential anti-inflammatory effects of medicinal cannabis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Cannabidiol for Mucosal Diseases: Therapeutic Potential and Advanced Delivery Strategies.Pharmaceutics · 2026Review
- Update of the statement on safety of cannabidiol as a novel food.EFSA journal. European Food Safety Authority · 2026Article
- Antiviral effect of cannabidiol on K18-hACE2 transgenic mice infected with SARS-CoV-2.Journal of cellular and molecular medicine · 2024Article
- Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.Scientific reports · 2024Article
- Immunomodulatory effects of cannabinoids against viral infections: a review of its potential use in SARS-CoV2 infection.Virusdisease · 2024Review
- An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.Molecules (Basel, Switzerland) · 2024Review
- The Use of Cannabidiol in Metabolic Syndrome-An Opportunity to Improve the Patient's Health or Much Ado about Nothing?Journal of clinical medicine · 2023Review
- Antiviral activities of hemp cannabinoids.Clinical science (London, England : 1979) · 2023Article
- Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment.Life (Basel, Switzerland) · 2022Review
- Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022).Pharmaceutics · 2022Review
- Cannabinoids as Emergent Therapy Against COVID-19.Cannabis and cannabinoid research · 2022Review
- In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir.Chemico-biological interactions · 2022Article
- The Prevalence of Dietary Supplement Use for the Purpose of COVID-19 Prevention in Japan.Nutrients · 2022Article
- Israeli news media coverage of COVID-19 and use of cannabis and tobacco: A case study of inconsistent risk communication.The International journal on drug policy · 2022Article
Corrections and comments
- Commented on by
Authors and funding
31 authors at 4 institutions in 4 countries.
José Alexandre S CrippaDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.ORCID 0000-0001-9520-6746
Julia Cozar PachecoDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Antonio W ZuardiDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Francisco S GuimarãesNational Institute for Science and Technology-Translational Medicine, São Paulo, Brazil.
Alline Cristina CamposDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Flávia de Lima OsórioDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Sonia Regina LoureiroDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Rafael G Dos SantosDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
José Diogo S SouzaDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Juliana Mayumi UshirohiraDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Rafael Rinaldi FerreiraDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Karla Cristinne Mancini CostaDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Davi Silveira ScomparinDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Franciele Franco ScaranteDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Isabela Pires-Dos-SantosDepartment of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Raphael MechoulamDepartment of Medicinal Chemistry and Natural Products, The Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
Flávio KapczinskiNational Institute for Science and Technology-Translational Medicine, São Paulo, Brazil.
Benedito A L FonsecaDepartment of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Danillo L A EspositoDepartment of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Afonso Dinis Costa PassosDepartment of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Amaury Lelis Dal FabbroDepartment of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Fernando Bellissimo-RodriguesDepartment of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Eurico ArrudaDepartment of Cell and Molecular Biology, and Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Sandro ScarpeliniDepartment of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Maristela Haddad AndrausChromatox Laboratory Ltda., São Paulo, Brazil.
Julio Cesar Nather JuniorDepartment of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Danilo Tadao WadaDepartment of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Marcel Koenigkam-SantosDepartment of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Antonio Carlos SantosDepartment of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Geraldo Busatto FilhoLaboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Jaime E C HallakDepartment of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Universidade de São Paulo · BRHebrew University of Jerusalem · ILTech Chrom (Brazil) · BRUniversidade Federal do Rio Grande do Sul · BR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
CannabidiolCOVID-19 Drug TreatmentAntiviral AgentsDouble-Blind MethodHumansSARS-CoV-2Antiviral AgentsCannabidiolcannabidiolclinical trialCOVID-19infectious diseasesinternal medicineSARS-CoV-2
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.